Background – Psoriasis is an inflammatory skin disease that affects 1%–3% of Caucasian populations and may be persistent, disfiguring and stigmatizing. Proton pump inhibitors (PPI) are potent blockers of gastric acid secretion. They are widely regarded as the agents of choice for the treatment of acid-peptic disorders. In addition to anti-secretory effects PPI have been found to have anti-oxidant properties and direct effects on neutrophils, monocytes, endothelial, and epithelial cells that might prevent inflammation. Objective – This study evaluated the treatment of psoriasis with esomeprazole.
Methods – Ten patients were selected and psoriasis was evaluated according to Psoriasis Area and Severity Index (PASI). Exclusion criteria included concomitant use of any treatment for Psoriasis, organic diseases, use of other PPI than esomeprazole. Patients were medicated with esomeprazole 40 mg B.I.D. for 90 days. At the 90th day the patients were evaluated according PASI score.
Results – Statistically significant results were seen when compared PASI before and at 90th day of treatment (P=0.0002).
Conclusion – The use of esomeprazole for psoriasis resulted in excellent clinical results with a significant reduction of PASI score.
HEADINGS – Psoriasis. Esomeprazole. Proton pump inhibitors.
Bafutto M, Oliveira EC, Zaterka S.
Arq Gastroenterol. 2019;56(3):260-2.
